Your browser doesn't support javascript.
loading
Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis.
Muro, Shigeo; Yoshisue, Hajime; Kostikas, Konstantinos; Olsson, Petter; Gupta, Pritam; Wedzicha, Jadwiga A.
Afiliación
  • Muro S; Department of Respiratory Medicine, Nara Medical University, Nara, Japan.
  • Yoshisue H; Novartis Pharma K.K. Japan, Tokyo, Japan.
  • Kostikas K; Respiratory Medicine Department, University of Ioannina Medical School, Ioannina, Greece.
  • Olsson P; Novartis Sverige AB, Kista, Sweden.
  • Gupta P; Novartis Healthcare Pvt. Ltd, Hyderabad, India.
  • Wedzicha JA; National Heart and Lung Institute, Imperial College London, London, UK.
Respirology ; 25(4): 393-400, 2020 04.
Article en En | MEDLINE | ID: mdl-31339215
BACKGROUND AND OBJECTIVE: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg once daily (q.d.) has demonstrated greater improvements in lung function, patient-reported outcomes and lower exacerbation rates versus mono long-acting muscarinic antagonists (LAMA) in chronic obstructive pulmonary disease (COPD) patients. However, data are limited on initial treatment with IND/GLY 110/50 µg q.d. versus mono LAMA in COPD patients, not previously on maintenance treatment with long-acting bronchodilators (LABD). METHODS: A pooled analysis of ARISE, SHINE and SPARK trials was conducted to evaluate the efficacy of IND/GLY 110/50 µg q.d. versus open-label (OL) tiotropium (TIO) 18 µg q.d. and GLY 50 µg q.d. in COPD patients, not on maintenance treatment with LABD at study entry (LABD-naïve). Efficacy was assessed after 24/26 weeks of treatment. RESULTS: In total, 998 LABD-naïve patients were included (IND/GLY: 353; OL TIO: 328; GLY: 317). Patients treated with IND/GLY 110/50 µg q.d. experienced greater improvements in trough forced expiratory volume in 1 s (FEV1 ) versus OL TIO 18 µg q.d. (least squares mean treatment difference (Δ): 0.086 L) and GLY 50 µg q.d. (Δ: 0.080 L) after 24/26 weeks. Improvements in electronic diary (eDiary) symptom scores, transition dyspnoea index (TDI) focal score, St George's Respiratory Questionnaire (SGRQ) total score and rescue medication use were also greater with IND/GLY versus OL TIO and GLY. Greater proportion of patients achieved minimal clinically important difference in trough FEV1 , TDI and SGRQ with IND/GLY versus OL TIO and GLY. CONCLUSION: LABD-naïve patients treated with IND/GLY 110/50 µg q.d. achieved improvements in lung function, daily symptoms, dyspnoea, health-related quality of life and rescue medication use versus those who received single LAMA.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinolonas / Enfermedad Pulmonar Obstructiva Crónica / Bromuro de Tiotropio / Glicopirrolato / Indanos Tipo de estudio: Clinical_trials / Etiology_studies Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Respirology Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinolonas / Enfermedad Pulmonar Obstructiva Crónica / Bromuro de Tiotropio / Glicopirrolato / Indanos Tipo de estudio: Clinical_trials / Etiology_studies Aspecto: Patient_preference Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Respirology Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Australia